Skip to content
Menu

Wedbush Maintains Outperform on Maze Therapeutics, Raises Price Target to $49

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wedbush analyst Laura Chico maintains Maze Therapeutics (NASDAQ:MAZE) with a Outperform and raises the price target from $48 to $49.

Wedbush analyst Laura Chico maintains Maze Therapeutics (NASDAQ:MAZE) with a Outperform and raises the price target from $48 to $49.

Read at benzinga.com